. Author manuscript; available in PMC: 2019 Mar 25.

Published in final edited form as: J Med Chem. 2017 Jun 27;60(13):5586–5598. doi: 10.1021/acs.jmedchem.7b00273

Table 1.

Antiproliferative Potencies (GI₅₀,^b nM) of 2 against the NCI-60 Panel^a

Leukemia		Colon Cancer		Ovarian Cancer		CNS Cancer
CCRF-CEM	0.551	COLO205	0.322	IGROV1	0.830	SF-268	0.788
HL-60(TB)	0.361	HCC-2998	0.371	OVCAR-3	0.266	SF-295	0.318
K562	0.359	HCT-116	0.369	OVCAR-4	2.43	SF-539	0.298
MOLT-4	0.605	HCT-15	0.413	OVCAR-5	>100	SNB-19	0.655
RPMI-8226	0.603	HT29	0.307	OVCAR-8	0.524	SNB-75	0.360
SR	0.301	KM12	0.353	NCI/ADR-RES	0.301	U251	0.437
Non-Small-Cell Lung Cancer		SW-620	0.487	SK-OV-3	0.409	Prostate Cancer
A549/ATCC	0.588	Melanoma		Renal Cancer		PC-3	0.636
EKVX	0.632	LOX IMVI	0.526	786–0	3.46	DU-145	0.409
HOP-62	0.690	MALME-3M	>100	A498	0.376	Breast Cancer
HOP-92	>100	M14	0.336	ACHN	0.926	MCF7	0.363
NCI-H226	3.03	MDA-MB-435	0.208	CAKI-1	0.497	MDA-MB-231/ATCC	0.914
NCI-H23	0.458	SK-MEL-28	>100	RXF-393	0.246	HS 578T	0.601
NCI-H322M	0.904	SK-MEL-5	0.400	SN12C	1.01	BT-549	2.10
NCI-H460	0.397	UACC-257	>100	TK-10	>100	T-47D	^c
NCI-H522	0.294	UACC-62	0.432	UO-31	10.0	MDA-MB-468	0.415

The data were provided by the NCI, USA. The TGI and LC₅₀ values are >1.0 × 10⁻⁷ M in most tested cell lines in the same assays (see SI).

The concentration that corresponds to 50% growth inhibition (GI₅₀).

Not available.